Improve balance through virtual reality
- Trial ID
- NCT07359716
- Official Title
- Virtual Reality Verses Conventional Physical Therapy in Parkinson's Disease Patients
- Goal
- Improve balance through virtual reality
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Montiha Azeem
- Study Type
- INTERVENTIONAL
- Enrollment
- 62 participants
- Conditions
- Parkinson s Disease
- Interventions
- Conventional Physical Therapy, Virtual Reality-Based Physical Therapy
Plain-Language Summary
The trial is testing whether virtual reality physical therapy can improve balance, gait and everyday mobility in people with Parkinson's better than conventional physical therapy, with the goal of reducing falls and making walking and balance easier. The VR sessions use simulated environments and real-time visual feedback to guide balance and gait exercises and track progress, while the conventional arm uses standard strength, balance and walking training; VR is meant to boost engagement and deliver precise movement cues that complement usual medications like levodopa. Eligible participants are men and women aged 45 to 65 with Parkinson's and good cognition, MMSE 24 or higher; people with other neurologic diseases, recent lower limb fractures, recent major peripheral surgery or trauma, or spinal cord injury are excluded.
Locations
- Shadman Medical Center, Lahore, Pakistan
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Conventional Physical Therapy. The trial is testing whether virtual reality physical therapy can improve balance, gait and everyday mobility in people with Parkinson's better than conventional physical therapy, with the goal of reducing falls and making walking and balance easier. The VR sessions use simulated environments and real-time visual feedback to guide balance and gait exercises and track progress, while the conventional arm uses standard strength, balance and walking training; VR is meant to boost engagement and deliver precise movement cues that complement usual medications like levodopa. Eligible participants are men and women aged 45 to 65 with Parkinson's and good cognition, MMSE 24 or higher; people with other neurologic diseases, recent lower limb fractures, recent major peripheral surgery or trauma, or spinal cord injury are excluded.
- Who can participate?
- Participants must be between 45 Years and 65 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 months.